Recurrent aphthous stomatitis (RAS) is a common condition characterised by recurrent episodes of oral ulceration.
Recurrent aphthous stomatitis (RAS) is a common condition characterised by recurrent episodes of oral ulceration. 1 Three clinical forms are described; 1,2 minor (MiRAS), major (MaRAS) and herpetiform ulceration (HU). MiRAS accounts for 80% of RAS patients. The ulcers are usually less than 5 mm in diameter, occur on the non-keratinised mucosa and heal spontaneously, without scarring, in 7-14 days.
The aetiology of RAS is unknown. Current evidence supports some form of immune dysfunction. 1 The earliest change is focal epithelial cell degeneration and intraepithelial vesicle formation. 3 A dense lympho-monocytic infiltrate develops adjacent to the damaged cells. Initially, CD4
+ T cells predominate but this changes to CD8 + during the ulcerative stage. 4 The majority are CD45RO + memory cells. 4 Adjacent keratinocytes become HLA-DR 5 and ICAM-1 positive and local blood vessels express Eselectin and VCAM-1. 6 These changes are consistent with release of pro-inflammatory cytokines such as IL-1, IL-6, TNF and interferon-␥. [6] [7] [8] Indeed, elevated levels of TNF␣, interferon-␥, IL-2, IL-4 and IL-5 have been detected in ulcer tissue 7, 8 and raised levels of IL-6 in the circulation. 9 It has been suggested that RAS is precipitated by local trauma in an individual genetically predisposed to an exaggerated or abnormal cytokine cascade. In turn, this leads to cytokine or cell-mediated damage to focal areas of the oral mucosa. 7 Other extrinsic factors may also Genetic factors also play an important role in the development of RAS. Twenty-four to 46% of patients report a positive family history 10 and parental RAS status strongly influences the probability of an individual suffering RAS. 11 Furthermore, there is significantly higher disease concordance in monozygotic than dizygotic twins. 12 Nevertheless, individual variability in disease susceptibility suggests a polygenic mode of inheritance 1, 11 with extrinsic factors such as trauma and smoking modulating disease expression.
The aim of this study was to investigate if MiRAS is associated with inheritance of IL-1A, IL-1B, IL-1RN or IL-6 gene polymorphisms.
Results and discussion

Study participants
Blood samples were obtained from 91 Caucasoid patients with MiRAS (mean age ± s.d. = 37.33 ± 24.64 years) comprising 30 men and 61 women. Only five were smokers. All subjects were assessed by an oral medicine specialist, and the presence of aphthous ulcers confirmed. Inclusion criteria included: (1) a 6-month or longer history of regularly recurrent episodes of oral aphthous ulceration; (2) at least two ulcers per month for the previous 6 months; (3) normal full blood count, serum B 12 (200-900 ng/l), red cell folate (110-700 g/l) and serum ferritin (20-400 g/l). Exclusion criteria included: (1) pregnancy; (2) history of systemic disease in which oral ulceration may be a feature eg, Behçet's syndrome, coeliac disease, Crohn's disease, ulcerative colitis or AIDS; (3) concurrent medication with systemic steroids, immunomodulatory drugs or cytotoxics; (4) a pattern of ulceration consistent with MaRAS or HU.
Blood samples were also obtained from 91 healthy ageand sex-matched Caucasoid controls selected from general medical practice registers. Although the controls were deemed healthy by their general medical practitioner, specific information on their RAS status was not available. It is therefore possible that a small proportion suffered from RAS. The inclusion of RAS patients would, however, result in an under estimate of the strength of any association identified. Because there were only five smokers in the patient group, it was not possible to look at the effect of smoking on any gene associations identified.
Gene associations IL-1A −889 and +4845 frequency distributions for cases and controls are presented in Table 1 . No significant difference in the allele or genotype frequencies of these two polymorphisms was observed. In contrast, the IL-1B −511 genotype frequencies were significantly different between cases and controls (P Ͻ 0.0002) ( Table 1) , due to an increased frequency of the *G allele in RAS cases (OR = 2.5; 95% CI 1.6-4.0; P Ͻ 0.00002). This was reflected in the significantly increased number of G/G homozygotes (OR 4.5; CI 1.9-10.9; P Ͻ 0.0005) among cases. In contrast, the IL-1B +3954 polymorphism did not encode risk for RAS.
Two SNPs within the IL-1B gene were examined; −511 and +3954 (the latter previously reported as position +3953 or +5887). IL-1B −511 was significantly associated with RAS but +3954 was not. Given their physical proximity, the association of IL-1B −511, but not +3954 seems confusing. However, the frequency of the +3954 T allele and T/T genotype was higher in RAS patients than controls but did not reach significance. Carriage of the IL-1B −511 G allele or the IL-1B +3954 T allele has been associated with greater production of IL-1␤, for a given stimulus, than the alternate alleles. 19, 20 As the +3954 polymorphism occurs in exon 5 of the gene and represents a conservative substitution it is unclear why this polymorphism should affect gene transcription. However, it may be because it is in linkage disequilibrium with polymorphisms in the regulatory region of the IL-1B gene. An earlier study has demonstrated linkage disequilibrium between IL-1B −511 and +3954, delta = 0.44. 21 Analysis of our control population confirmed this.
Another question raised by this study is why IL-1B, but not IL-1A, polymorphisms should be associated with RAS? IL-1␣ and IL-1␤ have almost identical actions but some subtle differences have been identified. Of note, IL-1B is transcribed to a greater degree than IL-1A in LPS stimulated neutrophils. 22 Also, IL-1B polymorphisms are more important in determining the risk of early onset periodontitis than IL-1A. 23 Another explanation could reside with the distribution of IL-1 receptors. Two receptors, IL-1R1 and IL-1R2, with different affinities for IL-1␣ and IL-1␤ have been described. 24, 25 Not all tissues express these receptors equally. The distribution of these receptors in oral tissues is not known but differences in receptor affinity and distribution could be important in explaining the association of IL-1B, but not IL-1A polymorphisms, with RAS. DNA was extracted from blood samples using the DNAce maxiblood systems (Bioline) and 100 ng amplified by PCR using the primers described in the references above. Reactions were performed in 25 l volumes with 100 M dNTPs, 6 pM primers and 1 U Taq polymerase (Bioline) for 35 cycles. With the exception of the IL-1RN 86 bp VNTR, genotypes were assigned by restriction enzyme digestion of the PCR products with 4 U of the appropriate enzyme (see references) in 15 l volume overnight. The digestion products were run out by electrophoresis on a 1% agarose gel containing ethidium bromide and visualised under UV light. PCR products for the IL-1RN 86 bp VNTR were directly run on the gel without restriction enzyme digestion. Each polymorphism was examined in the control population to confirm that the genotype distribution conformed to Hardy-Weinburg expectations. The distribution of alleles and genotypes for each polymorphism was compared between cases and controls using chi-square analysis and the appropriate degrees of freedom for biallelic polymorphisms. Examination of the IL-1RN 86 bp VNTR revealed a higher frequency of allele 1 in cases vs controls (71.4% vs 63.2%) and the 1/1 genotype occurred significantly more often in patients (OR = 2.0; 95% CI 1.1-3.6; P Ͻ 0.02) than controls. Confirmation of this association will require investigation of a further cohort.
Genes and Immunity
IL-1 and IL-1Ra compete for the same receptor and their ratio will determine if a given stimulus is proinflammatory or not. In this regard, it is important to note that individuals who are not carriers of IL-1RN allele 2 (eg, those who are 1/1 homozygous) have significantly lower levels of circulating IL-1Ra than those who are. 26 Furthermore, the lowest levels of IL-1Ra are found in those individuals who do not carry the IL-1RN allele 2 but do carry the IL-1B −511 G allele (ie the high IL-1␤ producer allele). 26 We found that the IL-1RN 86 bp VNTR 1/1 genotype occurred in combination with the IL-1B −511 G/G genotype or G allele with significantly higher frequency in patients than controls (15.1% vs 3.5% for 1/1 + G/G genotype (OR = 4.9, P Ͻ 0.02) and 40.7% vs 22.1% for 1/1 + G allele (OR = 2.4, P Ͻ 0.01)). It appears likely that the greatest degree of discordant regulation between IL-1␤ and IL-1Ra production occurs in individuals with these genotypes and could result in high levels of unopposed IL-1␤ activity. This could result in a more proinflammatory outcome following local trauma in RAS patients.
IL-6 −174 allele and genotype frequencies are summarised in Table 1 . A significant difference in the distribution of genotypes was observed in cases and controls (P Ͻ 0.0002). The *G allele occurred with significantly higher frequency in cases (P Ͻ 0.0001) and greatest risk of RAS was associated with G/G homozygosity (OR = 3.4; 95% CI 1.9-6.2; P Ͻ 0.0001). No significant association was noted with the IL-6 −573 polymorphism. Again, the IL-6 −174 and −573 polymorphisms are very close and an association with one might be expected to result in association with the other. However, the G allele at position −573 occurs in over 90% of the population. Thus an enormous sample size would be required to detect any association at this position.
The IL-6 −174 promoter polymorphism appears to be functional, lying immediately upstream of a multiresponse element at positions −173 to −151. This element is important in IL-1 and TNF modulated expression of IL-6 27 and inheritance of the G allele at position −174 has been shown to encode higher production of IL-6 than the C allele. 28 As IL-1B −511 and IL-6 −174 were both associated with RAS, the risk associated with inheriting the combined genotypes was examined (Table 2) . Homozygosity for G/G at IL-1B −511 and G/G at IL-6 −174 encoded an OR of 8.5. Thus individuals who are G homozygous at both loci have an eight-fold risk of developing RAS.
The three polymorphisms identified in this study are likely to be synergistic for increased IL-1␤ and IL-6 activity. Excessive or unopposed production of these cytokines in response to a local stimulus could be an important aetiological factor in RAS and could explain the elevated IL-6 plasma levels reported in this condition. 9 In turn, these cytokines are likely to induce production of other cytokines, such as TNF, that may also promote the disease process. It is notable that corticosteroids and thalidomide, two of the most effective therapeutic agents in RAS, are inhibitors of IL-1␤ and IL-6 production. [29] [30] [31] [32] The next step in these studies will be to determine if there is indeed higher unopposed IL-1 and IL-6 activity in patients with MiRAS and to see how this correlates with genotype.
